Last reviewed · How we verify
NCT05644769
Chymase Angiotensin-(1-12) Axis In Hypertensive Disease
Phase 4 trial testing Determine the presence of Human sequence Ang-(1-12) on no medication in Hypertension in 10 participants. Status unknown.
31 March 2023
Quick facts
| Lead sponsor | Trinity Hypertension & Metabolic Research Institute |
|---|---|
| Phase | Phase 4 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 10 |
| Start date | 15 November 2022 |
| Primary completion | 31 March 2023 |
| Estimated completion | 31 March 2023 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Determine the presence of Human sequence Ang-(1-12) on no medication
- Human sequence Ang-(1-12) on Lisinopril 40mg every day — full drug profile →
Conditions studied
- Hypertension — all drugs for Hypertension →
Sponsor
Trinity Hypertension & Metabolic Research Institute
Who can join
Adults 40 to 75, any sex, with Hypertension. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Determine the presence of the human sequence of Angiotensin-(1-12) in plasma of ten untreated hypertensive subjects and after 4 week with Lisinopril 40 mg every day. Determine the blood pressure reduction with Lisinopril 40mg.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05644769
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hypertension
Currently open trials in the same condition.
- NCT07413159 — The "Check, Monitor, Control Hypertension" Study is a 24-month Randomized Trial in Houston Targeting African Americans A · NA · recruiting
- NCT07361276 — Observational Study That Will Evaluate Treatment Patterns in the Management of Hypertension in the Public Primary Care S · recruiting
- NCT07238556 — A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors · NA · recruiting
- NCT07238400 — Cardiac Effects of Mineralocorticoid Receptor Antagonism After Preeclampsia · Phase 2 · recruiting
- NCT07135505 — Early Time-Restricted Eating in Older Adults With Hypertension · NA · recruiting
Other Trinity Hypertension & Metabolic Research Institute trials
Trials by the same sponsor.
- NCT06656806 — Efficacy and Safety of Inhaled NC-107 As Compared to Placebo After 4 Weeks of Treatment in Patients with Anxiety · EARLY_PHASE1 · not yet recruiting
- NCT03826745 — The CHYMASE Angiotensin-(1-12) Axis in Cardiovascular Disease · unknown
- NCT03180593 — Efficacy and Safety of Valsartan and Nebivolol/Valsartan in Hypertensive Patients With LVH · Phase 4 · completed
- NCT03635125 — Efficacy and Safety of Nebivolol Versus Metoprolol in Hypertensive Subject Taking Amlodipine · Phase 4 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05644769 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Trinity Hypertension & Metabolic Research Institute
- Last refreshed: 9 December 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05644769.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing